Today: 27 February 2026
Subscribe
Browse Category

NASDAQ:VNDA 31 December 2025 - 23 February 2026

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.
23 February 2026
··
Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

The Nasdaq Composite dropped 0.8% Wednesday to close 2025 at 23,241.99, while the S&P 500 lost 0.7% and the Dow fell 0.6%. U.S. markets are closed Thursday for New Year’s Day. Investors await the Jan. 9 jobs report, Jan. 13 inflation data, and the start of bank earnings for direction. Trading volume was below average, with tech and energy shares leading declines.
1 January 2026
····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.
31 December 2025
···
Go toTop